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Background: Surgical treatment for mycotic aortic aneurysms is not optimal. Even with a large excision, extensive
debridement, in situ or extra-anatomical reconstruction, and with or without lifelong antibiotic treatment, mycotic
aneurysms still carry very high mortality and morbidity. The use of endovascular aneurysm repair (EVAR) for mycotic
aortic aneurysms simplifies the procedure and provides a good alternative for this critical condition. However, the
question remains: if EVAR is placed in an infected bed, what is the outcome of the infection? Does it heal, become
aggravated, or even cause a disastrous aortic rupture? In this study, we tried to clarify the risk factors for such an adverse
response.
Methods: A literature review was undertaken by using MEDLINE. All relevant reports on endoluminal management of
mycotic aortic aneurysms were included. Logistic regressions were applied to identify predictors of persistent infection.
Results: A total of 48 cases from 22 reports were included. The life-table analysis showed that the 30-day survival rate was
89.6% 4.4%, and the 2-year survival rate was 82.2% 5.8%. By univariate analysis, age 65 years or older, rupture of the
aneurysm (including those with aortoenteric fistula and aortobronchial fistula), and fever at the time of operation were
identified as significant predictors of persistent infection, and preoperative use of antibiotics for longer than 1 week and
an adjunct procedure combined with EVAR were identified as significant protective factors for persistent infection.
However, by multivariate logistic regression analysis, the only significant independent predictors identified were rupture
of aneurysm and fever.
Conclusions: EVAR seems a possible alternative method for treating mycotic aortic aneurysms. Identification of the risk
factors for persistent infectionmay help to decrease surgical morbidity andmortality. EVAR could be used as a temporary
measure; however, a definite surgical treatment should be considered for patients present with aneurysm rupture or fever.
(J Vasc Surg 2007;46:906-12.)Mycotic aortic aneurysms are a rare subset (1%-1.8%) of
aortic aneurysms.1,2 Despite advances in antibiotic treat-
ment, purely medical management for mycotic aneurysms
is often inadequate because of the possibilities of persistent
infection, subsequent aneurysm rupture, and death.3 The
gold standard management strategy remains surgical resec-
tion and debridement of the infected aorta and the sur-
rounding tissues, the use of muscle flaps or omentum to
cover the infected field, and either an in situ interposition
graft or extra-anatomic bypass followed by long-term anti-
biotic therapy.3,4 However, surgical management in these
patients possesses high surgical risks and mortality (13.3%-
40%).3-6 Moreover, most patients with mycotic aneurysms
have significant comorbidities, resulting in a lethal risk for
major surgery.
In the past decade, endovascular aortic repair (EVAR)
for thoracic or abdominal aortic aneurysms has become
popular and has shown satisfactory results.7,8 Semba et al9
were the first to report successful treatment with EVAR in
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906three patients with mycotic aneurysms, and this was fol-
lowed by several other similar reports.10,11 Such a treat-
ment modality for mycotic aortic aneurysms would be
simpler than the conventional procedure and may be effec-
tive for saving lives. Thus, it seems to be a very good
alternative for treating patients with this critical illness.
However, two questions arise: can the residual infection
due to the lack of excision and debridement of the infected
nidi be overcome with antibiotic treatment alone, and
would the placement of a foreign body (EVAR) in an
infected bed aggravate the infection? It is clear that the
EVAR treatment for mycotic aortic aneurysms is not likely
to be widespread unless these questions are answered.
We therefore conducted a systematic analysis of the
reported cases of mycotic aortic aneurysms treated with
EVAR to determine the incidence of and risk factors for
persistent infection after treatment.
METHODS
Search strategy, data collection, and measurements
of outcomes. We performed an English language search
ofMEDLINE from January 1980 to January 2007 through
PUBMED by using the key words infected, mycotic, aorta,
aneurysm, and stent graft. We also reviewed the references
from the selected case reports. Twenty-five reports were
thoroughly reviewed; two studies that did not provide any
individual patient data and some duplicated reported cases
were excluded. We extracted data in total from 22 reports
that included 48 cases1,9-29 (Table I). All patients included
in the study were carefully reviewed for clinical details
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results, details of treatment, and early and late morbidity
and mortality. We accepted the original author’s definition
of an aneurysm as mycotic and included patients who
were culture negative. The healed patients were defined as
those who did not have fever, signs of sepsis, or hemorrhage
during follow-up. Treatment failure was defined as the
presence of persistent infections, including persistent sep-
ticemia, uncontrollable sepsis, recurrent fistula with bleed-
ing, and death secondary to persistent infection or compli-
cations of the mycotic aneurysms.
Primary data analysis. We analyzed the data by using
SPSS release 11.5.0 (SPSS Inc, Chicago, Ill). The explor-
atory data analyses checked the distribution of values and
for nominal data presented the results as a proportion
(percentage) of the total. Differences between patients with
persistent infection and those who had healed were evalu-
ated by using the 2 test or Fisher exact test for categorical
variables. A P value .1 was considered statistically signif-
icant, and all the statistical tests were two tailed. We calcu-
lated the odds ratios (ORs) to assess the relationship be-
tween potential predictors and outcomes. Multiple logistic
regression analysis was applied to adjust for confounding
variables, to obtain adjusted estimates of the ORs and 95%
confidence intervals (CI) for independent effects of the
potential predictors, and to identify significant independent
predictors of outcomes. The cumulative survival curve was
calculated by using the Kaplan-Meier method.
RESULTS
Characteristics of the patients. The study group in-
cluded 29 men and 19 women with a mean age of 63.85
years (range, 30-90 years) who had thoracic or abdominal
mycotic aortic aneurysms treated with methods involving
EVAR. The mean follow-up period for these patients was
22  19 months.
The pathologic lesions were located in the thoracic
aorta (n 32) and abdominal aorta (n 16). The reported
pathogens involved included salmonella (n  10), staphy-
lococci (n  10), streptococci (n  3), mycobacteria (n 
3), and other species (n  9), whereas in 13 patients the
infecting organism was not identified. Most patients re-
ceived broad-spectrum or sensitivity-specific antibiotics im-
mediately when an infected aneurysm was suspected.
Among these, 22 patients (45.8%) had received antibiotic
treatment for more than 1 week before they received
EVAR. Eighteen patients (37.5%) received emergency
EVAR treatments because of symptoms of rupture, and in
most of these patients, the bleeding stopped immediately
after the EVAR procedure. Twenty-one patients (43.7%)
had fever (body temperature 37.5°C) at the time they
received the stent. Thirteen patients (37.1%) received re-
lated procedures in addition to their EVAR, including
soaking stents in antibiotics, receiving drainage cannulas,
and debriding with or without irrigation. Persistent infec-
tions occurred in 11 patients (22.9%), whose presentations
included prolonged fever with no other symptoms (n 1),
uncontrolled sepsis (n 7), and rupture or bleeding events(n  6). The 30-day mortality rate of EVAR treatment for
mycotic aortic aneurysms due to sepsis or massive bleeding
was 10.4% (five patients). Of the five late mortalities
(10.4%), two died of cardiac disease, and three died with
graft-related bleeding problems (Table I). In addition, the
12-month actual survival rate of the healed group was
94.0%  4.0%, and that of the persistently infected group
was 39.0% 17.0%, a significant difference (Fig; P  .05).
Parameters for predicting persistent infection. We
divided the 48 patients into 2 groups: the healed (n  37)
and those with persistent infection (n  11). The median
follow-up periods for the entire group, the healed group,
and the persistent infection group were 15, 17, and 5
months, respectively. Various parameters relevant to the
clinical outcome were analyzed (Table II). Univariate anal-
ysis identified the following parameters as significant pre-
dictors for persistent infection: age 65 years or older (OR,
7.39; 95% CI, 1.39-39.27), ruptured aneurysms (including
those with aortoenteric fistulas and aortobronchial fistulas;
OR, 4.14; 95% CI, 1.00-17.05), fever the at time of oper-
ation (OR, 4.92; 95% CI, 1.11-21.82), use of preoperative
antibiotics for longer than 1 week (OR, 0.19; 95% CI,
0.04-1.00), and an adjunct procedure combined with
EVAR therapy (OR, 0.65; 95% CI, 0.51-0.82). The last
two parameters seemed to be protective factors. We further
evaluated predictive parameters for persistent infection by
using multiple logistic regression analysis by including all
the predictors with a P value .1 in the univariate analyses
in a full model (Table III). From this we constructed the
final model, which included only the predictors shown as
significant in the multivariate analysis. The significant inde-
pendent predictors associated with persistent infection in
EVAR treatment for mycotic aortic aneurysms included
rupture and fever at the time of operation.
DISCUSSION
Management of mycotic aortic aneurysms remains a
challenging clinical problem for cardiovascular surgeons.
Hsu et al30 suggest that advanced age, infection with
non-Salmonella species, and no surgical intervention are
the major determinants for mortality in mycotic aortic
aneurysms. Fillmore and Valentine31 determined that
sepsis is the leading cause of death for surgical infected
aneurysm patients and that a combination of host- and
infection-specific variables may be more predictive of out-
comes than any single risk factor. Discouraged by the high
morbidity and mortality of standard surgical procedures in
this disease, Semba et al9 first proposed EVAR as an alter-
nate approach. Several subsequent reports suggest that
EVAR in the management of mycotic aortic aneurysms
provides a viable, less invasive alternative with favorable
results.10,11,15 The procedure has significant advantages
over open surgery as it avoids a large incision, full hepa-
rinization, extracorporeal circulation, aortic cross-clamp-
ing, interference with respiratory function, and the need for
massive blood transfusion.32 However, putting an endo-
vascular graft in an infected environment is controversial
and against general surgical principles. If the infection
tics ta
erculo
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irremediable disaster. For these reasons, the basis for suc-
cessful application of EVAR for mycotic aneurysms inter-
ested us.
Several explanations have been proposed for the suc-
cessful use of EVAR in mycotic aortic aneurysms. First,
broad-spectrum antibiotics are administered as soon as a
mycotic aortic aneurysm is suspected. This is usually fol-
lowed by the appropriate antibiotics determined by culture
Table I. All cases summary
Study Patient age (y)/sex
Ting11 87/M SA 
37/M SA
59/M Salm
68/M Can
77/M Salm
59/M Not
90/M Not
Alpagut12 38/M Not
Forbes13 73/M Salm
83/F Salm
Jorna14 79/F Stre
Lee15 65/F SA 
58/M GNB
56/M TB
30/F Ente
85/M SA
Corso1 62/M SA 
Gonzalez-Fajardo16 75/M Not
68/M Salm
Sayed17 46/F Not
77/F Not
50/F Not
Jones10 64/F Not
62/M Not
60/F Salm
69/F Not
72/F Not
80/M Salm
40/M Pneu
Koeppel18 47/M Salm
Kotzampassakis19 84/F Salm
Rayan20 51/M SA 
Bell21 76/M SA 
Stanely22 64/M Stre
62/M SA
77/M Ente
79/F Stre
Van Doorn23 66/F Clos
Ischida24 81/F SA 
Berchtold25 60/M Salm
Bond26 58/F Not
Liu27 42/F TB 
41/M TB
Madhaven28 50/M SA 
Kinney29 55/F Esch
Semba9 64/M Prot
70/M Not
69/F Clos
AEF, Aortoenteric fistula; ABF, aortobronchial fistula; ACF, aortocutane
37.5°C; MI, myocardial infarction; A/B, preoperative intravenous antibio
AAA, abdominal aorta; GNB, gram-negative bacilli; TB, Mycobacterium tuband sensitivity testing, which might eradicate many bacte-ria. Thus, many authors suggest that EVAR is feasible when
antibiotic suppression has achieved negative blood cultures
before surgery.10,33 Second, as reported by Jones et al10
and as indicated in our summarized data, no microbes
could be isolated from blood and tissue cultures in 25% to
40% of mycotic aortic aneurysms. Third, the use of antibiotic-
coated grafts to reduce the source of infection or of a coated
endoprosthesis to release antibiotics into the blood stream
has also been proposed to account for the success.14,22,32
anism Rupture Site Fever
AEF TAo 
No TAo 
a sp No TAo 
albicans AEF TAo 
a No TAo 
en AEF TAo 
en No TAo 
en No TAo 
a sp No AAA 
a sp No AAA 
cus sp CR TAo 
No AAA 
No AAA 
No AAA 
cus GNB No TAo 
AEF AAA 
CR AAA 
en AEF AAA 
a sp AEF TAo 
en No TAo 
en ABF TAo 
en ABF TAo 
en No TAo 
en No TAo 
a sp No TAo 
en ACF TAo 
en ABF TAo 
a sp No AAA 
ccus sp No TAo 
a sp No AAA 
a sp ABF TAo 
CR TAo 
No TAo 
cus sp No TAo 
No TAo 
cus sp FR TAo 
cus sp No AAA 
m septicum AEF TAo 
FR TAo 
a sp No AAA 
en AEF TAo 
No AAA 
FR AAA 
No AAA 
a coli No AAA 
irabilis ABF TAo 
en No TAo 
m septicum FR TAo 
stula; CR, contained rupture; FR, free rupture; fever, body temperature
ken for longer than 1 week; SA, Staphylococcus aureus; TAo, thoracic aorta;
sis.Org
onell
dida
onell
prov
prov
 prov
onell
onell
ptococ
rococ
 prov
onell
 prov
prov
prov
 prov
prov
onell
prov
prov
onell
moco
onell
onell
ptococ
rococ
ptococ
tridiu
onell
 prov
erichi
eus m
prov
tridiu
ous fiFourth, adjunct procedures such as surgical debridement or
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tive and an important step in eliminating the source of
infection.15 Finally, prolonged postoperative antibiotic
therapy is also advocated as a key component for suc-
cess,11,15 but there is no consensus on the optimal dura-
tion of antibiotic therapy. Most commonly, parenteral
antibiotics are given for 2 to 8 weeks after surgery,
but whether lifelong oral antibiotics are necessary is
debated.4,15,17
The clinical results after EVAR for mycotic aortic
Table I. Continued
A/B Adjunctive procedure FU (mo
 — 3
 — 38
 — 35
 Thoracotomy, debridement 34
 — 7
 — 3
 — 4
 — 7
 — 48
 — 5
 Soaked in rifampicin 6
 Drainage catheter 36
 — 48
 Drainage catheter 96
 — 0
 — 0
 — 12
 — 2
 — 0
 — 12
 Open aortotomy 26
 — 12
 — 56
 — 0
 — 36
 — 5
 — 28
 — 27
 — 16
 Drainage 12
 — 6
 — 7
 — 42
 Soaked in vancomycin 12
 — 15
 — 10
 — 2
 Debridement irrigations 24
 — 0
 — 48
 — 62
 — 24
 Surgical drainage 18
 Combine op excision 12
 Drainage 10
 Combine op excision 25
 Combined surgery AAA 24
 Debridement 4
Combine op excision, this surgery is combined with EVAR and open surgeaneurysms—deduced from the accumulated data in thisreport—show only 5 postoperative deaths (5/48; 10.4%)
and 5 late deaths (5/48; 10.4%). Additionally, compared
with the 70% 12-month survival rate in traditional surgical
results of infected aortic aneurysm reported by Hsu et al,30
an important observation is that the 12-month survival rate
for the healed group after EVAR is 94%, thus suggesting
that when successful EVAR treatment is achieved for my-
cotic aortic aneurysms, it might yield a better clinical out-
come than conventional surgery.3-6 Furthermore, because
up to 60% of mycotic aneurysms may present as ruptured,34
Persistent infection Mortality
Sepsis —
— —
— —
— —
— —
Stent-graft infection —
— —
— —
— —
Sepsis/bacteremia —
— —
— —
— —
— —
AEF/sepsis 30 d
Rebleeding/sepsis 30 d
— —
Sepsis 2 mp
Sepsis/bleeding 30 d
— —
— —
— —
— —
— 30 d (rupture)
— —
Rebleeding 5 mo
— —
Rebleeding —
— —
— —
— —
— —
Persistent fever —
— —
— —
— —
— —
— —
Rupture, sepsis 30 d
— —
— 62 mo (hematemesis)
— —
— —
— —
— 10 mo (MI)
— 25 mo (cardiac arrest)
— —
— —
ision for low abdominal aneurysm.)
ry excEVAR can be used as a temporary measure to quickly
Meier method.
OR, Odds ratio; CI, confidence interval; DM, diabetes mellitus; Pre/Post IV A/B
OR, Odds ratio; CI, confidence interval; Pre IV A/B, preoperative intravenous an
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possibly allow further definitive surgical treatment.15,17,23
Unfortunately, patients who showed persistent infec-
tion after EVAR treatment had a 12-month survival rate of
only 39.0%. Thus, information that might allow identifica-
tion of such patients predisposed to persistent infection
after EVAR would be highly appreciated. Our univariate
analysis revealed that age 65 years or older, ruptured aneu-
rysms (including those with aortoenteric fistulas and aorto-
bronchial fistulas), and fever at the time of operation are
significant parameters related to the incidence of persistent
infection in EVAR treatment for mycotic aortic aneurysms.
Aging strongly correlates with a cluster of risk factors and
with multiple organ dysfunction35,36: just as age is an
independent determinant of mortality in cardiac surgery, it
also plays an important role in EVAR procedures. Lee
et al15 pointed out that major factors contributing to
unfavorable results of EVAR are the presence of aortoen-
teric fistula and active infection. A well-known axiom states
that surgical treatment for ruptured aortic aneurysms car-
y endovascular stent graft
Healed
(n  37)
P value OR (95% CI)%
59.46% 1.000 1.19 (0.30-4.80)
37.84% .010 7.39 (1.39-39.27)
21.62% 1.000 0.81 (0.14-4.50)
29.73% .702 0.53 (0.10-2.84)
13.51% .653 1.42 (0.24-8.59)
13.51% 1.000 0.64 (0.07-6.14)
48.65% .514 0.60 (0.15-2.42)
72.97% 1.000 0.99 (0.22-4.48)
18.92% .675 1.607 (0.337-7.658)
29.73% .041 4.14 (1.00-17.05)
32.43% 1.000 1.19 (0.29-4.87)
35.14% .027 4.92 (1.11-21.82)
70.27% .163 0.35 (0.09-1.40)
54.05% .036 0.19 (0.04-1.00)
48.65% .514 0.60 (0.15-2.42)
35.14% .023 0.65 (0.51-0.82)
21.62% .022 6.34 (1.48-27.22)
2.70% .007 20.57 (1.99-212.72)
13.89% .046 9.00 (1.19-68.13)
8.33% .180 4.40 (0.58-33.21)
, preoperative/postoperative intravenous antibiotic use.
n problems
Final model, OR (95% CI) P value
—
7.93 (1.29-48.87) .026
6.88 (1.07-44.14) .042
—
—Fig. Actuarial survival of study subjects, calculated by the Kaplan-Table II. Demographics of infected aortic aneurysms treated b
Variable
Persistent infection
(n  11)
n % n
Male sex 7 63.64% 22
Age 65 y 9 81.82% 14
DM 2 18.18% 8
Heart disease 2 18.18% 11
Cancer 2 18.18% 5
Osteomyelitis 1 9.09% 5
Pain 4 36.36% 18
Positive culture 8 72.73% 27
Salmonella spp 3 27.27% 7
Ruptured aneurysm 7 63.64% 11
Diseased site (thoracic) 4 36.36% 12
Fever at operation 8 72.73% 13
Pre IV A/B 5 45.45% 26
Pre IV A/B 1 wk 2 18.18% 20
Post IV A/B 4 wk 4 36.36% 18
Adjunctive procedure 0 0.00% 13
Early complication 7 63.64% 8
30-d mortality 4 36.36% 1
Late complication (n  40) 3 42.86% 5
Late mortality (n  40) 2 28.57% 3Table III. Predictive factors associated with persistent infectio
Risk factors Full model, OR (95% CI)
Age 65 y 7.39 (1.39-39.27)
Ruptured aneurysm 4.14 (1.00-17.05)
Fever at operation 4.92 (1.11-21.82)
Protective factors
Pre IV A/B 1 wk 0.19 (0.04-1.00)
Adjunctive procedure 0.65 (0.51-0.82)tibiotic use.
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procedures.37 Aneurysm rupture indicates that the patient
is in a critical condition and that the surrounding tissues
may have been extensively damaged. These patients often
need emergency treatment without the chance of any ad-
ditional therapy. Fever at the time of operation indicates
that patients have an active infection or that infection is not
well controlled by antibiotics. By contrast, preoperative
antibiotic use for longer than 1 week combined with ad-
junct procedures might have significant protective effects.
The treatment protocol for infective endocarditis38,39 has
shown us that if we can administer sufficient preoperative
antibiotics to control the infection, surgical results will be
improved.
Routine preoperative antibiotics might not completely
suppress bacterial activity, whereas a longer period of pre-
operative antibiotics may have a better chance of eradicat-
ing the infection. Although postoperative antibiotics also
do not guarantee that the foci of infection are eradicated,
the results of EVAR in such situations are impressive.12
Adjunct procedures assist in eliminating the infective foci to
decrease the rate of persistent infection,15,22 but they
might also indicate that patients are in a worse condition
and need additional therapy to achieve the therapeutic
goals. However, further multivariate analysis revealed that
many of these factors interact and that ruptured aneurysms
and fever at operation are the only significant independent
predictors associated with persistent infection in EVAR
treatment for mycotic aortic aneurysms.
CONCLUSION
This study summarized all cases of EVAR treatment for
mycotic aortic aneurysms reported in the literature, ana-
lyzed the risk factors for occurrence of persistent infection,
and followed up the clinical results of this technique. The
most important finding of this meta-analysis is that persis-
tent infection after EVAR treatment of mycotic aortic
aneurysms is closely associated with a poor prognosis. From
the results of the analysis, we identified aneurysm rupture
and fever at operation as the most significant variables
associated with the occurrence of persistent infection in
these patients. When patients present with rupture or have
fever, the EVAR method should be considered as a tempo-
rary measure to achieve hemodynamic stability. Addition-
ally, if the fever persists after the EVAR, a definite surgical
treatment should be considered. However, further multi-
institutional and registry data are required to clarify the
long-term outcomes of EVAR and to determine whether
EVAR use in mycotic aortic aneurysms is as effective as or
better than standard surgical care.
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